nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Parkinson's disease—Bromocriptine—type 2 diabetes mellitus	0.807	1	CpDpCtD
Trihexyphenidyl—Ileus paralytic—Miglitol—type 2 diabetes mellitus	0.00712	0.0639	CcSEcCtD
Trihexyphenidyl—Neuroleptic malignant syndrome—Bromocriptine—type 2 diabetes mellitus	0.00275	0.0247	CcSEcCtD
Trihexyphenidyl—Blindness—Glyburide—type 2 diabetes mellitus	0.00232	0.0208	CcSEcCtD
Trihexyphenidyl—Paranoia—Bromocriptine—type 2 diabetes mellitus	0.00206	0.0185	CcSEcCtD
Trihexyphenidyl—Delusion—Bromocriptine—type 2 diabetes mellitus	0.00199	0.0178	CcSEcCtD
Trihexyphenidyl—Sinus bradycardia—Losartan—type 2 diabetes mellitus	0.00175	0.0157	CcSEcCtD
Trihexyphenidyl—Blindness—Irbesartan—type 2 diabetes mellitus	0.00165	0.0148	CcSEcCtD
Trihexyphenidyl—Memory impairment—Losartan—type 2 diabetes mellitus	0.00109	0.00981	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Bromocriptine—type 2 diabetes mellitus	0.000997	0.00895	CcSEcCtD
Trihexyphenidyl—Constipation—Miglitol—type 2 diabetes mellitus	0.000939	0.00843	CcSEcCtD
Trihexyphenidyl—Drowsiness—Glipizide—type 2 diabetes mellitus	0.000935	0.00838	CcSEcCtD
Trihexyphenidyl—Weight decreased—Pioglitazone—type 2 diabetes mellitus	0.000908	0.00815	CcSEcCtD
Trihexyphenidyl—Drowsiness—Glimepiride—type 2 diabetes mellitus	0.000872	0.00782	CcSEcCtD
Trihexyphenidyl—Drowsiness—Bromocriptine—type 2 diabetes mellitus	0.000787	0.00706	CcSEcCtD
Trihexyphenidyl—Dry skin—Gliclazide—type 2 diabetes mellitus	0.000768	0.00689	CcSEcCtD
Trihexyphenidyl—Constipation—Linagliptin—type 2 diabetes mellitus	0.00076	0.00682	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Tolazamide—type 2 diabetes mellitus	0.00074	0.00664	CcSEcCtD
Trihexyphenidyl—Constipation—Acarbose—type 2 diabetes mellitus	0.000738	0.00662	CcSEcCtD
Trihexyphenidyl—Tension—Glipizide—type 2 diabetes mellitus	0.000717	0.00643	CcSEcCtD
Trihexyphenidyl—Nervousness—Glipizide—type 2 diabetes mellitus	0.000709	0.00636	CcSEcCtD
Trihexyphenidyl—Hallucination—Bromocriptine—type 2 diabetes mellitus	0.000703	0.0063	CcSEcCtD
Trihexyphenidyl—Dry skin—Orlistat—type 2 diabetes mellitus	0.000697	0.00626	CcSEcCtD
Trihexyphenidyl—Rash—Miglitol—type 2 diabetes mellitus	0.000692	0.00621	CcSEcCtD
Trihexyphenidyl—Dermatitis—Miglitol—type 2 diabetes mellitus	0.000692	0.00621	CcSEcCtD
Trihexyphenidyl—Vision blurred—Glipizide—type 2 diabetes mellitus	0.000688	0.00618	CcSEcCtD
Trihexyphenidyl—Tension—Glimepiride—type 2 diabetes mellitus	0.000669	0.006	CcSEcCtD
Trihexyphenidyl—Tension—Sitagliptin—type 2 diabetes mellitus	0.000667	0.00598	CcSEcCtD
Trihexyphenidyl—Nervousness—Glimepiride—type 2 diabetes mellitus	0.000662	0.00594	CcSEcCtD
Trihexyphenidyl—Nervousness—Sitagliptin—type 2 diabetes mellitus	0.00066	0.00592	CcSEcCtD
Trihexyphenidyl—Nausea—Miglitol—type 2 diabetes mellitus	0.000652	0.00585	CcSEcCtD
Trihexyphenidyl—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.000646	0.00579	CcSEcCtD
Trihexyphenidyl—Asthenia—Tolazamide—type 2 diabetes mellitus	0.000645	0.00578	CcSEcCtD
Trihexyphenidyl—Vision blurred—Glimepiride—type 2 diabetes mellitus	0.000642	0.00576	CcSEcCtD
Trihexyphenidyl—Vision blurred—Sitagliptin—type 2 diabetes mellitus	0.00064	0.00574	CcSEcCtD
Trihexyphenidyl—Agitation—Glimepiride—type 2 diabetes mellitus	0.000626	0.00562	CcSEcCtD
Trihexyphenidyl—Rash—Tolbutamide—type 2 diabetes mellitus	0.000623	0.00559	CcSEcCtD
Trihexyphenidyl—Headache—Tolbutamide—type 2 diabetes mellitus	0.000619	0.00555	CcSEcCtD
Trihexyphenidyl—Constipation—Repaglinide—type 2 diabetes mellitus	0.000616	0.00553	CcSEcCtD
Trihexyphenidyl—Tension—Bromocriptine—type 2 diabetes mellitus	0.000603	0.00541	CcSEcCtD
Trihexyphenidyl—Confusional state—Glipizide—type 2 diabetes mellitus	0.000601	0.00539	CcSEcCtD
Trihexyphenidyl—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000597	0.00536	CcSEcCtD
Trihexyphenidyl—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.000597	0.00536	CcSEcCtD
Trihexyphenidyl—Dizziness—Tolazamide—type 2 diabetes mellitus	0.000594	0.00533	CcSEcCtD
Trihexyphenidyl—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.000594	0.00533	CcSEcCtD
Trihexyphenidyl—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000587	0.00526	CcSEcCtD
Trihexyphenidyl—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.000582	0.00522	CcSEcCtD
Trihexyphenidyl—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.000579	0.0052	CcSEcCtD
Trihexyphenidyl—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.000571	0.00512	CcSEcCtD
Trihexyphenidyl—Dry skin—Losartan—type 2 diabetes mellitus	0.000571	0.00512	CcSEcCtD
Trihexyphenidyl—Rash—Tolazamide—type 2 diabetes mellitus	0.000566	0.00508	CcSEcCtD
Trihexyphenidyl—Rash—Chlorpropamide—type 2 diabetes mellitus	0.000566	0.00508	CcSEcCtD
Trihexyphenidyl—Agitation—Bromocriptine—type 2 diabetes mellitus	0.000565	0.00507	CcSEcCtD
Trihexyphenidyl—Headache—Chlorpropamide—type 2 diabetes mellitus	0.000563	0.00505	CcSEcCtD
Trihexyphenidyl—Headache—Tolazamide—type 2 diabetes mellitus	0.000563	0.00505	CcSEcCtD
Trihexyphenidyl—Confusional state—Glimepiride—type 2 diabetes mellitus	0.000561	0.00503	CcSEcCtD
Trihexyphenidyl—Rash—Linagliptin—type 2 diabetes mellitus	0.000561	0.00503	CcSEcCtD
Trihexyphenidyl—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.00056	0.00503	CcSEcCtD
Trihexyphenidyl—Headache—Linagliptin—type 2 diabetes mellitus	0.000557	0.005	CcSEcCtD
Trihexyphenidyl—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00055	0.00494	CcSEcCtD
Trihexyphenidyl—Vomiting—Acarbose—type 2 diabetes mellitus	0.000549	0.00492	CcSEcCtD
Trihexyphenidyl—Rash—Acarbose—type 2 diabetes mellitus	0.000544	0.00488	CcSEcCtD
Trihexyphenidyl—Dermatitis—Acarbose—type 2 diabetes mellitus	0.000544	0.00488	CcSEcCtD
Trihexyphenidyl—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000543	0.00487	CcSEcCtD
Trihexyphenidyl—Drowsiness—Metformin—type 2 diabetes mellitus	0.00054	0.00485	CcSEcCtD
Trihexyphenidyl—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000534	0.00479	CcSEcCtD
Trihexyphenidyl—Nausea—Tolazamide—type 2 diabetes mellitus	0.000534	0.00479	CcSEcCtD
Trihexyphenidyl—Somnolence—Glipizide—type 2 diabetes mellitus	0.00053	0.00475	CcSEcCtD
Trihexyphenidyl—Vision blurred—Glyburide—type 2 diabetes mellitus	0.00053	0.00475	CcSEcCtD
Trihexyphenidyl—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000529	0.00475	CcSEcCtD
Trihexyphenidyl—Rash—Nateglinide—type 2 diabetes mellitus	0.000525	0.00471	CcSEcCtD
Trihexyphenidyl—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.000524	0.0047	CcSEcCtD
Trihexyphenidyl—Nausea—Acarbose—type 2 diabetes mellitus	0.000513	0.0046	CcSEcCtD
Trihexyphenidyl—Constipation—Glipizide—type 2 diabetes mellitus	0.00051	0.00457	CcSEcCtD
Trihexyphenidyl—Confusional state—Bromocriptine—type 2 diabetes mellitus	0.000506	0.00454	CcSEcCtD
Trihexyphenidyl—Tension—Gliclazide—type 2 diabetes mellitus	0.000495	0.00444	CcSEcCtD
Trihexyphenidyl—Somnolence—Glimepiride—type 2 diabetes mellitus	0.000494	0.00444	CcSEcCtD
Trihexyphenidyl—Nausea—Nateglinide—type 2 diabetes mellitus	0.000494	0.00444	CcSEcCtD
Trihexyphenidyl—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.000493	0.00442	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.000491	0.00441	CcSEcCtD
Trihexyphenidyl—Nervousness—Gliclazide—type 2 diabetes mellitus	0.00049	0.0044	CcSEcCtD
Trihexyphenidyl—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00049	0.00439	CcSEcCtD
Trihexyphenidyl—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000488	0.00438	CcSEcCtD
Trihexyphenidyl—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000474	0.00425	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.000471	0.00422	CcSEcCtD
Trihexyphenidyl—Agitation—Gliclazide—type 2 diabetes mellitus	0.000464	0.00416	CcSEcCtD
Trihexyphenidyl—Confusional state—Glyburide—type 2 diabetes mellitus	0.000463	0.00415	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.000458	0.00411	CcSEcCtD
Trihexyphenidyl—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000458	0.00411	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.000457	0.0041	CcSEcCtD
Trihexyphenidyl—Rash—Repaglinide—type 2 diabetes mellitus	0.000454	0.00408	CcSEcCtD
Trihexyphenidyl—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000454	0.00407	CcSEcCtD
Trihexyphenidyl—Headache—Repaglinide—type 2 diabetes mellitus	0.000451	0.00405	CcSEcCtD
Trihexyphenidyl—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00045	0.00404	CcSEcCtD
Trihexyphenidyl—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000446	0.004	CcSEcCtD
Trihexyphenidyl—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000437	0.00392	CcSEcCtD
Trihexyphenidyl—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000432	0.00387	CcSEcCtD
Trihexyphenidyl—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000429	0.00385	CcSEcCtD
Trihexyphenidyl—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000429	0.00385	CcSEcCtD
Trihexyphenidyl—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000429	0.00385	CcSEcCtD
Trihexyphenidyl—Nausea—Repaglinide—type 2 diabetes mellitus	0.000428	0.00384	CcSEcCtD
Trihexyphenidyl—Asthenia—Glipizide—type 2 diabetes mellitus	0.000428	0.00384	CcSEcCtD
Trihexyphenidyl—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000427	0.00383	CcSEcCtD
Trihexyphenidyl—Confusional state—Gliclazide—type 2 diabetes mellitus	0.000415	0.00373	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000413	0.00371	CcSEcCtD
Trihexyphenidyl—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00041	0.00368	CcSEcCtD
Trihexyphenidyl—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000404	0.00363	CcSEcCtD
Trihexyphenidyl—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000402	0.00361	CcSEcCtD
Trihexyphenidyl—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000399	0.00358	CcSEcCtD
Trihexyphenidyl—Vision blurred—Metformin—type 2 diabetes mellitus	0.000398	0.00357	CcSEcCtD
Trihexyphenidyl—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000398	0.00357	CcSEcCtD
Trihexyphenidyl—Dizziness—Glipizide—type 2 diabetes mellitus	0.000394	0.00354	CcSEcCtD
Trihexyphenidyl—Tension—Irbesartan—type 2 diabetes mellitus	0.000391	0.00351	CcSEcCtD
Trihexyphenidyl—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000387	0.00347	CcSEcCtD
Trihexyphenidyl—Vomiting—Glipizide—type 2 diabetes mellitus	0.000379	0.0034	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000378	0.00339	CcSEcCtD
Trihexyphenidyl—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000378	0.00339	CcSEcCtD
Trihexyphenidyl—Rash—Glipizide—type 2 diabetes mellitus	0.000376	0.00337	CcSEcCtD
Trihexyphenidyl—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000376	0.00337	CcSEcCtD
Trihexyphenidyl—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000375	0.00337	CcSEcCtD
Trihexyphenidyl—Headache—Glipizide—type 2 diabetes mellitus	0.000373	0.00335	CcSEcCtD
Trihexyphenidyl—Tension—Losartan—type 2 diabetes mellitus	0.000368	0.0033	CcSEcCtD
Trihexyphenidyl—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000368	0.0033	CcSEcCtD
Trihexyphenidyl—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000367	0.00329	CcSEcCtD
Trihexyphenidyl—Agitation—Irbesartan—type 2 diabetes mellitus	0.000366	0.00329	CcSEcCtD
Trihexyphenidyl—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000366	0.00329	CcSEcCtD
Trihexyphenidyl—Nervousness—Losartan—type 2 diabetes mellitus	0.000364	0.00327	CcSEcCtD
Trihexyphenidyl—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.00036	0.00323	CcSEcCtD
Trihexyphenidyl—Headache—Pioglitazone—type 2 diabetes mellitus	0.000358	0.00321	CcSEcCtD
Trihexyphenidyl—Nausea—Glipizide—type 2 diabetes mellitus	0.000354	0.00318	CcSEcCtD
Trihexyphenidyl—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000354	0.00317	CcSEcCtD
Trihexyphenidyl—Vision blurred—Losartan—type 2 diabetes mellitus	0.000353	0.00317	CcSEcCtD
Trihexyphenidyl—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000353	0.00316	CcSEcCtD
Trihexyphenidyl—Constipation—Gliclazide—type 2 diabetes mellitus	0.000352	0.00316	CcSEcCtD
Trihexyphenidyl—Rash—Glimepiride—type 2 diabetes mellitus	0.000351	0.00315	CcSEcCtD
Trihexyphenidyl—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00035	0.00314	CcSEcCtD
Trihexyphenidyl—Rash—Sitagliptin—type 2 diabetes mellitus	0.00035	0.00314	CcSEcCtD
Trihexyphenidyl—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000349	0.00313	CcSEcCtD
Trihexyphenidyl—Headache—Glimepiride—type 2 diabetes mellitus	0.000348	0.00313	CcSEcCtD
Trihexyphenidyl—Headache—Sitagliptin—type 2 diabetes mellitus	0.000347	0.00312	CcSEcCtD
Trihexyphenidyl—Agitation—Losartan—type 2 diabetes mellitus	0.000345	0.00309	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000339	0.00305	CcSEcCtD
Trihexyphenidyl—Somnolence—Valsartan—type 2 diabetes mellitus	0.000336	0.00302	CcSEcCtD
Trihexyphenidyl—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000332	0.00298	CcSEcCtD
Trihexyphenidyl—Nausea—Glimepiride—type 2 diabetes mellitus	0.00033	0.00296	CcSEcCtD
Trihexyphenidyl—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000329	0.00295	CcSEcCtD
Trihexyphenidyl—Asthenia—Glyburide—type 2 diabetes mellitus	0.000329	0.00295	CcSEcCtD
Trihexyphenidyl—Constipation—Valsartan—type 2 diabetes mellitus	0.000324	0.0029	CcSEcCtD
Trihexyphenidyl—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000319	0.00286	CcSEcCtD
Trihexyphenidyl—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000317	0.00285	CcSEcCtD
Trihexyphenidyl—Rash—Bromocriptine—type 2 diabetes mellitus	0.000316	0.00284	CcSEcCtD
Trihexyphenidyl—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000316	0.00284	CcSEcCtD
Trihexyphenidyl—Tension—Ramipril—type 2 diabetes mellitus	0.000316	0.00283	CcSEcCtD
Trihexyphenidyl—Headache—Bromocriptine—type 2 diabetes mellitus	0.000314	0.00282	CcSEcCtD
Trihexyphenidyl—Nervousness—Ramipril—type 2 diabetes mellitus	0.000312	0.0028	CcSEcCtD
Trihexyphenidyl—Confusional state—Losartan—type 2 diabetes mellitus	0.000309	0.00277	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000308	0.00276	CcSEcCtD
Trihexyphenidyl—Somnolence—Metformin—type 2 diabetes mellitus	0.000306	0.00275	CcSEcCtD
Trihexyphenidyl—Tachycardia—Losartan—type 2 diabetes mellitus	0.000299	0.00268	CcSEcCtD
Trihexyphenidyl—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000298	0.00267	CcSEcCtD
Trihexyphenidyl—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000296	0.00265	CcSEcCtD
Trihexyphenidyl—Agitation—Ramipril—type 2 diabetes mellitus	0.000295	0.00265	CcSEcCtD
Trihexyphenidyl—Constipation—Metformin—type 2 diabetes mellitus	0.000295	0.00264	CcSEcCtD
Trihexyphenidyl—Vomiting—Glyburide—type 2 diabetes mellitus	0.000292	0.00262	CcSEcCtD
Trihexyphenidyl—Rash—Glyburide—type 2 diabetes mellitus	0.000289	0.00259	CcSEcCtD
Trihexyphenidyl—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000289	0.00259	CcSEcCtD
Trihexyphenidyl—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000289	0.00259	CcSEcCtD
Trihexyphenidyl—Headache—Glyburide—type 2 diabetes mellitus	0.000287	0.00258	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000284	0.00255	CcSEcCtD
Trihexyphenidyl—Constipation—Irbesartan—type 2 diabetes mellitus	0.000278	0.0025	CcSEcCtD
Trihexyphenidyl—Nausea—Glyburide—type 2 diabetes mellitus	0.000272	0.00244	CcSEcCtD
Trihexyphenidyl—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000272	0.00244	CcSEcCtD
Trihexyphenidyl—Somnolence—Losartan—type 2 diabetes mellitus	0.000272	0.00244	CcSEcCtD
Trihexyphenidyl—Asthenia—Valsartan—type 2 diabetes mellitus	0.000272	0.00244	CcSEcCtD
Trihexyphenidyl—Asthenia—Orlistat—type 2 diabetes mellitus	0.000268	0.00241	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000268	0.0024	CcSEcCtD
Trihexyphenidyl—Confusional state—Ramipril—type 2 diabetes mellitus	0.000265	0.00237	CcSEcCtD
Trihexyphenidyl—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000262	0.00235	CcSEcCtD
Trihexyphenidyl—Constipation—Losartan—type 2 diabetes mellitus	0.000262	0.00235	CcSEcCtD
Trihexyphenidyl—Rash—Gliclazide—type 2 diabetes mellitus	0.00026	0.00233	CcSEcCtD
Trihexyphenidyl—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000259	0.00233	CcSEcCtD
Trihexyphenidyl—Headache—Gliclazide—type 2 diabetes mellitus	0.000258	0.00232	CcSEcCtD
Trihexyphenidyl—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000256	0.0023	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000252	0.00226	CcSEcCtD
Trihexyphenidyl—Dizziness—Valsartan—type 2 diabetes mellitus	0.00025	0.00225	CcSEcCtD
Trihexyphenidyl—Dizziness—Orlistat—type 2 diabetes mellitus	0.000247	0.00222	CcSEcCtD
Trihexyphenidyl—Asthenia—Metformin—type 2 diabetes mellitus	0.000247	0.00222	CcSEcCtD
Trihexyphenidyl—Nausea—Gliclazide—type 2 diabetes mellitus	0.000245	0.0022	CcSEcCtD
Trihexyphenidyl—Vomiting—Valsartan—type 2 diabetes mellitus	0.000241	0.00216	CcSEcCtD
Trihexyphenidyl—Rash—Valsartan—type 2 diabetes mellitus	0.000239	0.00214	CcSEcCtD
Trihexyphenidyl—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000238	0.00214	CcSEcCtD
Trihexyphenidyl—Vomiting—Orlistat—type 2 diabetes mellitus	0.000238	0.00213	CcSEcCtD
Trihexyphenidyl—Headache—Valsartan—type 2 diabetes mellitus	0.000237	0.00213	CcSEcCtD
Trihexyphenidyl—Rash—Orlistat—type 2 diabetes mellitus	0.000236	0.00212	CcSEcCtD
Trihexyphenidyl—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000236	0.00211	CcSEcCtD
Trihexyphenidyl—Headache—Orlistat—type 2 diabetes mellitus	0.000234	0.0021	CcSEcCtD
Trihexyphenidyl—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000233	0.00209	CcSEcCtD
Trihexyphenidyl—Somnolence—Ramipril—type 2 diabetes mellitus	0.000233	0.00209	CcSEcCtD
Trihexyphenidyl—Dizziness—Metformin—type 2 diabetes mellitus	0.000228	0.00204	CcSEcCtD
Trihexyphenidyl—Nausea—Valsartan—type 2 diabetes mellitus	0.000225	0.00202	CcSEcCtD
Trihexyphenidyl—Constipation—Ramipril—type 2 diabetes mellitus	0.000224	0.00201	CcSEcCtD
Trihexyphenidyl—Nausea—Orlistat—type 2 diabetes mellitus	0.000222	0.00199	CcSEcCtD
Trihexyphenidyl—Asthenia—Losartan—type 2 diabetes mellitus	0.00022	0.00197	CcSEcCtD
Trihexyphenidyl—Vomiting—Metformin—type 2 diabetes mellitus	0.000219	0.00197	CcSEcCtD
Trihexyphenidyl—Rash—Metformin—type 2 diabetes mellitus	0.000217	0.00195	CcSEcCtD
Trihexyphenidyl—Dermatitis—Metformin—type 2 diabetes mellitus	0.000217	0.00195	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000216	0.00194	CcSEcCtD
Trihexyphenidyl—Headache—Metformin—type 2 diabetes mellitus	0.000216	0.00194	CcSEcCtD
Trihexyphenidyl—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000215	0.00193	CcSEcCtD
Trihexyphenidyl—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000207	0.00186	CcSEcCtD
Trihexyphenidyl—Rash—Irbesartan—type 2 diabetes mellitus	0.000205	0.00184	CcSEcCtD
Trihexyphenidyl—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000205	0.00184	CcSEcCtD
Trihexyphenidyl—Nausea—Metformin—type 2 diabetes mellitus	0.000205	0.00184	CcSEcCtD
Trihexyphenidyl—Headache—Irbesartan—type 2 diabetes mellitus	0.000204	0.00183	CcSEcCtD
Trihexyphenidyl—Dizziness—Losartan—type 2 diabetes mellitus	0.000202	0.00182	CcSEcCtD
Trihexyphenidyl—Vomiting—Losartan—type 2 diabetes mellitus	0.000195	0.00175	CcSEcCtD
Trihexyphenidyl—Nausea—Irbesartan—type 2 diabetes mellitus	0.000193	0.00173	CcSEcCtD
Trihexyphenidyl—Rash—Losartan—type 2 diabetes mellitus	0.000193	0.00173	CcSEcCtD
Trihexyphenidyl—Dermatitis—Losartan—type 2 diabetes mellitus	0.000193	0.00173	CcSEcCtD
Trihexyphenidyl—Headache—Losartan—type 2 diabetes mellitus	0.000192	0.00172	CcSEcCtD
Trihexyphenidyl—Asthenia—Ramipril—type 2 diabetes mellitus	0.000188	0.00169	CcSEcCtD
Trihexyphenidyl—Nausea—Losartan—type 2 diabetes mellitus	0.000182	0.00163	CcSEcCtD
Trihexyphenidyl—Dizziness—Ramipril—type 2 diabetes mellitus	0.000174	0.00156	CcSEcCtD
Trihexyphenidyl—Vomiting—Ramipril—type 2 diabetes mellitus	0.000167	0.0015	CcSEcCtD
Trihexyphenidyl—Rash—Ramipril—type 2 diabetes mellitus	0.000165	0.00148	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000165	0.00148	CcSEcCtD
Trihexyphenidyl—Headache—Ramipril—type 2 diabetes mellitus	0.000164	0.00148	CcSEcCtD
Trihexyphenidyl—Nausea—Ramipril—type 2 diabetes mellitus	0.000156	0.0014	CcSEcCtD
Trihexyphenidyl—CHRM5—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.24e-05	0.000153	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.23e-05	0.000152	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—GNB3—type 2 diabetes mellitus	1.22e-05	0.000151	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.22e-05	0.000151	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.22e-05	0.000151	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—HMOX1—type 2 diabetes mellitus	1.22e-05	0.00015	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.21e-05	0.000149	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.2e-05	0.000149	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.2e-05	0.000148	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.2e-05	0.000148	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CAT—type 2 diabetes mellitus	1.2e-05	0.000148	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.19e-05	0.000147	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—C3—type 2 diabetes mellitus	1.19e-05	0.000147	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.19e-05	0.000147	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.19e-05	0.000147	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.19e-05	0.000146	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.19e-05	0.000146	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.18e-05	0.000146	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—GCG—type 2 diabetes mellitus	1.18e-05	0.000146	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.18e-05	0.000146	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AGT—type 2 diabetes mellitus	1.18e-05	0.000146	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.17e-05	0.000145	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—GCG—type 2 diabetes mellitus	1.17e-05	0.000145	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.17e-05	0.000144	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.17e-05	0.000144	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.17e-05	0.000144	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—APOB—type 2 diabetes mellitus	1.16e-05	0.000144	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.16e-05	0.000143	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.16e-05	0.000143	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—LEP—type 2 diabetes mellitus	1.16e-05	0.000143	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—APOE—type 2 diabetes mellitus	1.16e-05	0.000143	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.15e-05	0.000142	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.15e-05	0.000142	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.15e-05	0.000141	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.14e-05	0.00014	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.13e-05	0.00014	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AGT—type 2 diabetes mellitus	1.13e-05	0.00014	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—GSTM1—type 2 diabetes mellitus	1.13e-05	0.00014	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—LPL—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—LEP—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—APOE—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.11e-05	0.000137	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.1e-05	0.000135	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.1e-05	0.000135	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.09e-05	0.000135	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.09e-05	0.000135	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.09e-05	0.000135	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.09e-05	0.000134	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ADCY5—type 2 diabetes mellitus	1.09e-05	0.000134	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.09e-05	0.000134	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—GPX1—type 2 diabetes mellitus	1.08e-05	0.000134	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.08e-05	0.000133	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.08e-05	0.000133	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CD36—type 2 diabetes mellitus	1.06e-05	0.00013	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.05e-05	0.000129	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	1.04e-05	0.000129	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.03e-05	0.000128	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.03e-05	0.000128	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.03e-05	0.000127	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.02e-05	0.000126	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.02e-05	0.000126	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.02e-05	0.000126	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.01e-05	0.000125	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.01e-05	0.000125	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	1.01e-05	0.000125	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.01e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	1.01e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.01e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	1e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1e-05	0.000124	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	1e-05	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.98e-06	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	9.97e-06	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.97e-06	0.000123	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.93e-06	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.91e-06	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—INS—type 2 diabetes mellitus	9.9e-06	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.9e-06	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.89e-06	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.88e-06	0.000122	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	9.82e-06	0.000121	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.78e-06	0.000121	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	9.77e-06	0.00012	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.74e-06	0.00012	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	9.73e-06	0.00012	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.73e-06	0.00012	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.69e-06	0.00012	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	9.64e-06	0.000119	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.61e-06	0.000119	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.6e-06	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.58e-06	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.58e-06	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.57e-06	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—EGFR—type 2 diabetes mellitus	9.53e-06	0.000118	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	9.51e-06	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.49e-06	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—INS—type 2 diabetes mellitus	9.48e-06	0.000117	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	9.35e-06	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.33e-06	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	9.32e-06	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	9.32e-06	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	9.29e-06	0.000115	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	9.21e-06	0.000114	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	9.2e-06	0.000114	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IGF1—type 2 diabetes mellitus	9.17e-06	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT2—type 2 diabetes mellitus	9.17e-06	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.13e-06	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	9.13e-06	0.000113	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.1e-06	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	9.1e-06	0.000112	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.01e-06	0.000111	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.75e-06	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.72e-06	0.000108	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.71e-06	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.68e-06	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.68e-06	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.64e-06	0.000107	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.59e-06	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.56e-06	0.000106	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.48e-06	0.000105	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	8.4e-06	0.000104	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	8.37e-06	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.32e-06	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.32e-06	0.000103	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	8.29e-06	0.000102	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—RELA—type 2 diabetes mellitus	8.17e-06	0.000101	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	8.12e-06	0.0001	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.01e-06	9.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.99e-06	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.98e-06	9.85e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	7.98e-06	9.84e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.96e-06	9.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—INS—type 2 diabetes mellitus	7.96e-06	9.82e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	7.95e-06	9.81e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.9e-06	9.75e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.88e-06	9.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	7.87e-06	9.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.84e-06	9.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	7.83e-06	9.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.82e-06	9.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	7.82e-06	9.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	7.82e-06	9.64e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	7.79e-06	9.61e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	7.79e-06	9.61e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.74e-06	9.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.73e-06	9.53e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	7.72e-06	9.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	7.72e-06	9.52e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.7e-06	9.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.63e-06	9.41e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.44e-06	9.18e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.37e-06	9.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.37e-06	9.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.35e-06	9.06e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.32e-06	9.04e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	7.3e-06	9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.28e-06	8.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.13e-06	8.79e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.06e-06	8.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.01e-06	8.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	6.98e-06	8.61e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	6.98e-06	8.61e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.97e-06	8.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.97e-06	8.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.95e-06	8.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.89e-06	8.5e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.88e-06	8.49e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.76e-06	8.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	6.68e-06	8.24e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.67e-06	8.23e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	6.66e-06	8.21e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.6e-06	8.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	6.59e-06	8.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.57e-06	8.1e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.55e-06	8.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.49e-06	8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.47e-06	7.98e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.46e-06	7.97e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.45e-06	7.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.44e-06	7.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.43e-06	7.94e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.43e-06	7.93e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	6.42e-06	7.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.41e-06	7.9e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	6.38e-06	7.88e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.38e-06	7.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.37e-06	7.86e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.34e-06	7.83e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.26e-06	7.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	6.15e-06	7.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.13e-06	7.57e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.11e-06	7.54e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.05e-06	7.47e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.99e-06	7.39e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.86e-06	7.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.86e-06	7.22e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.84e-06	7.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.84e-06	7.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.78e-06	7.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.78e-06	7.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.74e-06	7.08e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.63e-06	6.95e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	5.51e-06	6.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.5e-06	6.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	5.49e-06	6.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	5.44e-06	6.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.39e-06	6.65e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.02e-06	6.19e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5e-06	6.17e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.97e-06	6.13e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.96e-06	6.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.95e-06	6.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.94e-06	6.09e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.92e-06	6.07e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.91e-06	6.05e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.88e-06	6.01e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.7e-06	5.8e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.68e-06	5.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.65e-06	5.73e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.64e-06	5.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.63e-06	5.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.59e-06	5.66e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.56e-06	5.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.54e-06	5.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.5e-06	5.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.33e-06	5.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	4.33e-06	5.34e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	4.32e-06	5.33e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	4.28e-06	5.27e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.22e-06	5.2e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.21e-06	5.19e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.16e-06	5.14e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	4.14e-06	5.11e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.99e-06	4.92e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.87e-06	4.78e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.86e-06	4.76e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.82e-06	4.72e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.82e-06	4.71e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.8e-06	4.68e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.78e-06	4.67e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.75e-06	4.62e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	3.21e-06	3.96e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.92e-06	3.6e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.91e-06	3.59e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.88e-06	3.55e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.69e-06	3.32e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.68e-06	3.31e-05	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.66e-06	3.28e-05	CbGpPWpGaD
